fibrinopeptide-a and Glomerulonephritis

A study on the significance of the measurement of fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 (FPB beta) in urine and plasma before and after urokinase (UK) administration in patients with chronic glomerulonephritis is described. FPA and FPB beta in urine and plasma were measured by radioimmunoassay. The levels of fibrinogen degradation product (FDP) in urine and sera were also determined before and after the UK administration. UK was administered at a dose of 48,000 IU/20 ml in saline intravenously, followed by an intravenous infusion of 250 ml of 5% glucose for one hour. It was demonstrated that the levels of FPB beta in urine and plasma showed a significant increase after UK administration in patients with chronic glomerulonephritis. However, there was no significant difference in the levels of FDP in urine and sera before and after UK administration. It was concluded that the measurement of FPB beta in urine and plasma may be useful for evaluating the efficacy of UK therapy in patients with chronic glomerulonephritis.

Topics: Adult; Chronic Disease; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinopeptide A; Fibrinopeptide B; Glomerulonephritis; Glomerulonephritis, IGA; Humans; Peptide Fragments; Urokinase-Type Plasminogen Activator

Plasma fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 concentrations were determined by radioimmunoassay in 46 patients with glomerulonephritis and the nephrotic syndrome. An increase in plasma FPA and B beta 15-42 levels was noted in these patients; this increase was marked in the nephrotic patients. There was a positive correlation in these patients between plasma FPA and B beta 15-42 levels. The B beta 15-42/FPA ratio was significantly higher in nonnephrotic patients compared with controls. Intravascular coagulation with subsequent fibrinolysis to regulate fibrin formation may occur in patients. A positive correlation was found between plasma B beta 15-42 level and serum urea nitrogen or serum creatinine concentration, suggesting that plasma B beta 15-42 level is influenced not only by plasmin action, but also by renal dysfunction.

Topics: Adolescent; Adult; Blood Coagulation; Blood Urea Nitrogen; Cholesterol; Creatinine; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Fibrinopeptide A; Fibrinopeptide B; Glomerulonephritis; Humans; Middle Aged; Nephrotic Syndrome; Peptide Fragments; Radioimmunoassay; Serum Albumin

Topics: Adult; Aged; Chronic Disease; Drug Evaluation; Female; Fibrinogen; Fibrinopeptide A; Fibrinopeptide B; Glomerulonephritis; Humans; Male; Middle Aged; Urokinase-Type Plasminogen Activator

Topics: Blood Coagulation; Fibrin Fibrinogen Degradation Products; Fibrinopeptide A; Glomerulonephritis; Humans